{"entity":{"id":"nct05997017","kind":"trial","name":"Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer","aka":[],"tldr":"A phase 2 trial of Sirolimus protein-bound particles in endometrial cancer, run by Aadi Bioscience, Inc., now recruiting.","summary":"Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer is a phase 2 interventional study registered as NCT05997017 by Aadi Bioscience, Inc., with 29 participants planned, started 2023-12-28 and due to reach its primary completion in 2026-12. Interventions recorded: nab-sirolimus. Conditions listed: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05997017","url":"https://clinicaltrials.gov/study/NCT05997017"}],"tags":["ctgov-ingest"],"related":[],"cancers":["endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":["sirolimus-albumin-bound"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05997017","phase":"2","setting":"A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer","sponsor":"Aadi Bioscience, Inc.","enrolled":29,"outcomes":[]},"route":"/trials/nct05997017/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"drug":[{"id":"sirolimus-albumin-bound","kind":"drug","name":"Sirolimus protein-bound particles","route":"/drugs/sirolimus-albumin-bound/"}]}}